Nuclidium

Basel, Switzerland · Founded 2017 · Privately Held (backing)

Developer of novel radiopharmaceutical tracers designed to target cancer diagnostics. Nuclidium is based in Basel, Switzerland and was founded in 2017. Its last reported valuation was $163 million in Jul 2025. It has raised $101 million.

Last reported valuation

$163.2M

Oct 2026

Priced at

—

Total raised

$100.6M

Last round

—

How much has Nuclidium raised?

$100.6Macross 0 recorded rounds

Free account

More of Nuclidium with a free account

·The complete investor list: 13 names
·Watch Nuclidium: the Monday email on marks, rounds and moves

Create free account

No card required

Membership and data by Private Market View

Nuclidium investors

13 investors are on record for Nuclidium, including Innosuisse, Bayern Kapital, Highlight Capital and NRW.Bank. By type, the record holds 5 venture capital firms.

For fundraisers

Raising for a company like Nuclidium?

13 investors have backed Nuclidium.

See all 13 investors →

Frequently asked about Nuclidium

How much has Nuclidium raised?: Nuclidium has raised $100.6M in total across 0 recorded funding rounds.